目的探讨血清壳多糖酶3样蛋白1(chitinase-3-like protein 1,CHI3L1)、甲胎蛋白(alpha fetoprotein,AFP)和γ-谷氨酰转移酶(γ-glutamyl transferase,GGT)检测在乙型肝炎病毒(hepatitis B virus,HBV)感染相关肝癌诊断中的临床应用价值...目的探讨血清壳多糖酶3样蛋白1(chitinase-3-like protein 1,CHI3L1)、甲胎蛋白(alpha fetoprotein,AFP)和γ-谷氨酰转移酶(γ-glutamyl transferase,GGT)检测在乙型肝炎病毒(hepatitis B virus,HBV)感染相关肝癌诊断中的临床应用价值。方法选取2021年7月—2023年7月在玉林市第一人民医院就诊HBV病毒感染相关的50例肝癌患者,50例肝硬化患者,50例慢性乙型肝炎患者以及50名同期健康体检者作为研究对象。比较4组研究对象血清中CHI3L1、AFP、GGT、丙氨酸氨基转移酶(alanine aminotransferase,ALT)、天门冬氨酸氨基转移酶(aspartate aminotransferase,AST)等水平的差异,用受试者工作特征(receiver operating characteristic curve,ROC)曲线评估各指标在肝癌中的诊断价值。结果肝炎组、肝硬化组、肝癌组的CHI3L1、AST、ALT水平均高于对照组,肝癌组AFP、GGT水平高于对照组,差异有统计学意义(P<0.05)。与肝炎组比较,肝硬化组及肝癌组的CHI3L1、AFP、GGT、AST、ALT水平均升高,差异有统计学意义(P<0.05)。与肝硬化组比较,肝癌组的CHI3L1、AFP、GGT、AST水平均升高,差异有统计学意义(P<0.05)。ROC曲线分析显示,CHI3L1、AFP、GGT联合时的曲线下面积(area under the curve,AUC)最大(AUC=0.936)。Spearman相关分析结果显示,CHI3L1与AST呈正相关(r=0.414,P=0.003),AFP与GGT呈正相关(r=0.437,P=0.002),AFP与AST呈正相关(r=0.504,P<0.001),GGT与AST呈正相关(r=0.759,P<0.001),GGT与ALT呈正相关(r=0.636,P<0.001)。结论CHI3L1、AFP及GGT联合检测可提高肝癌的诊断价值,对临床肝癌患者诊疗有重要作用。展开更多
Background:Serum chitinase-3-like protein 1(CHI3L1)is a potential biomarker for fibrosis assessment.We aimed to evaluate serum CHI3L1 as a noninvasive diagnostic marker for chronic hepatitis B virusrelated fibrosis.Me...Background:Serum chitinase-3-like protein 1(CHI3L1)is a potential biomarker for fibrosis assessment.We aimed to evaluate serum CHI3L1 as a noninvasive diagnostic marker for chronic hepatitis B virusrelated fibrosis.Methods:Serum CHI3L1 levels were measured by ELISA in 134 chronic hepatitis B(CHB)patients.Significant fibrosis was defined as a liver stiffness>9.7 kPa.The performance of CHI3L1 was assessed and compared to that of other noninvasive tests by receiver operating characteristic(ROC)analysis.Results:Serum CHI3L1 levels were significantly higher in CHB patients with significant hepatic fibrosis(≥F2)than in those without significant hepatic fibrosis(<F2)(56.5 ng/mL vs.81.9 ng/mL,P<0.001).In CHB patients,the specificity and sensitivity of CHI3L1 for predicting significant fibrosis were 75.6%and 59.1%,respectively,with a cut-off of 76.0 ng/mL and an area under the ROC curve of 0.728(95%CI:0.637–0.820).Conclusions:Serum CHI3L1 levels could be an effective new serological biomarker for the diagnosis of liver fibrosis.Moreover,CHI3L1 is feasible in monitoring disease progression.展开更多
目的:基于以壳多糖酶3样蛋白1(chitinase-3-like protein 1,CHI3L1)为主要评价指标,观察化肝纤方联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床疗效。方法:将80例确诊为慢性乙型肝炎肝纤维化的患者采用随机数字表法的方式分为对照组和治...目的:基于以壳多糖酶3样蛋白1(chitinase-3-like protein 1,CHI3L1)为主要评价指标,观察化肝纤方联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床疗效。方法:将80例确诊为慢性乙型肝炎肝纤维化的患者采用随机数字表法的方式分为对照组和治疗组各40例,2组均采用一般西医综合治疗,治疗组在此基础上仅加用化肝纤方,疗程为8周,比较2组治疗前后的血清CHI3L1水平、肝功能(转氨酶、总胆红素)、肝纤4项、Fibrosis 4 Score(FIB-4指数)、肝脏硬度值(liver stiffness measurement,LSM)、乙肝病毒DNA(hepatitis B virus-DNA,HBV-DNA)转阴率、中医症状评分等观察指标。结果:治疗后治疗组血清CHI3L1水平、肝功能(转氨酶、总胆红素)、肝纤4项、FIB-4指数、肝脏硬度值、HBV-DNA转阴率、中医症状评分均低于对照组,差异有统计学意义。结论:化肝纤方联合恩替卡韦治疗慢性乙型肝炎相关肝纤维化有较好的临床疗效,可改善慢性乙型肝炎肝纤维化患者肝脏生理水平及肝纤维化程度,降低血清CHI3L1、肝纤4项、FBI-4指数、肝脏硬度值,提高乙肝病毒DNA转阴率,改善肝功能及临床症状,延缓疾病的进展,提高患者生存质量。展开更多
AIM:To evaluate the potential of two trabecular meshwork(TM)-specific promoters,Chitinase 3-like 1(Ch3L1)and matrix gla protein(MGP),for improving specificity and safety in glaucoma gene therapy based on self-compleme...AIM:To evaluate the potential of two trabecular meshwork(TM)-specific promoters,Chitinase 3-like 1(Ch3L1)and matrix gla protein(MGP),for improving specificity and safety in glaucoma gene therapy based on self-complementary AAV2(scAAV2)vector technologies.METHODS:An scAAV2 vector with C3 transferase(C3)as the reporter gene(scAAV2-C3)was selected.The scAAV2-C3 vectors were driven by Ch3L1(scAAV2-Ch3L1-C3),MGP(scAAV2-MGP-C3),enhanced MGP(scAAV2-eMGP-C3)and cytomegalovirus(scAAV2-CMV-C3),respectively.The cultured primary human TM cells were treated with each vector at different multiplicities of infections.Changes in cell morphology were observed by phase contrast microscopy.Actin stress fibers and Rho GTPases/Rho-associated protein kinase pathway-related molecules were assessed by immunofluorescence staining,real-time quantitative polymerase chain reaction and Western blot.Each vector was injected intracamerally into the one eye of each rat at low and high doses respectively.In vivo green fluorescence was visualized by a Micron III Retinal Imaging Microscope.Intraocular pressure(IOP)was monitored using a rebound tonometer.Ocular responses were evaluated by slit-lamp microscopy.Ocular histopathology analysis was examined by hematoxylin and eosin staining.RESULTS:In TM cell culture studies,the vectormediated C3 expression induced morphologic changes,disruption of actin cytoskeleton and reduction of fibronectin expression in TM cells by inhibiting the Rho GTPases/Rhoassociated protein kinase signaling pathway.At the same dose,these changes were significant in TM cells treated with scAAV2-CMV-C3 or scAAV2-Ch3L1-C3,but not in cells treated with scAAV2-eMGP-C3 or scAAV2-MGP-C3.At lowinjected dose,the IOP was significantly decreased in the scAAV2-Ch3L1-C3-injected eyes but not in scAAV2-MGPC3-injected and scAAV2-eMGP-C3-injected eyes.At highinjected dose,significant IOP reduction was observed in the scAAV2-eMGP-C3-injected eyes but not in scAAV2-MGP-C3-injected eyes.Similar to scAAV2-CMV-C3,scAAV2-Ch3L1-C3 vector showed efficient transduction both in the TM and corneal endothelium.In anterior segment tissues of scAAV2-eMGP-C3-injected eyes,no obvious morphological changes were found except for the TM.Inflammation was absent.CONCLUSION:In scAAV2-transduced TM cells,the promoter-driven efficiency of Ch3L1 is close to that of cytomegalovirus,but obviously higher than that of MGP.In the anterior chamber of rat eye,the transgene expression pattern of scAAV2 vector is presumably affected by MGP promoter,but not by Ch3L1 promoter.These findings would provide a useful reference for improvement of specificity and safety in glaucoma gene therapy using scAAV2 vector.展开更多
目的:观察Hp阳性消化性溃疡患者血清壳多糖酶3样蛋白1(chitosanase 3-like protein 1,CHI3L1)水平的变化,分析其临床意义。方法:选择本院消化内科2020年2月—2023年2月期间收治的136例消化性溃疡患者为研究对象,其中Hp阳性87例(Hp阳性组...目的:观察Hp阳性消化性溃疡患者血清壳多糖酶3样蛋白1(chitosanase 3-like protein 1,CHI3L1)水平的变化,分析其临床意义。方法:选择本院消化内科2020年2月—2023年2月期间收治的136例消化性溃疡患者为研究对象,其中Hp阳性87例(Hp阳性组)、Hp阴性49例(Hp阴性组),并将Hp阳性组分为Hp感染Ⅰ型(59例)、Hp感染Ⅱ型(28例)。比较Hp阳性组、Hp阴性组的年龄、性别、病情程度、吸烟史、饮酒史、饮食习惯、血清CHI3L1、转化生长因子-β1(transforming growth factor-β1,TGF-β1)、胃蛋白酶原(pepsinogen,PG)Ⅰ、PGⅡ等资料,并比较Hp阳性组不同病变部位、Hp感染类型、病情分期患者血清CHI3L1水平。分析消化性溃疡Hp感染的相关因素及血清CHI3L1水平对消化性溃疡Hp感染的诊断价值。结果:Hp阳性组血清CHI3L1、TGF-β1、PGⅠ、PGⅡ水平均高于Hp阴性组(P<0.01);Hp感染Ⅰ型患者血清CHI3L1水平高于Hp感染Ⅱ型患者(P<0.01);复合溃疡患者血清CHI3L1水平高于胃溃疡和十二指肠溃疡患者(P<0.01);活动期患者血清CHI3L1水平高于愈合期和瘢痕期(P<0.01),愈合期高于瘢痕期(P<0.01)。多因素logistic回归分析发现血清CHI3L1、TGF-β1、PGⅠ、PGⅡ水平均为消化性溃疡患者合并Hp感染的独立危险因素;ROC曲线分析显示,CHI3L1诊断消化性溃疡患者Hp感染的最佳截断值为96.22 ng/mL,灵敏度、特异度分别为79.82%、86.11%,曲线下面积为0.902。结论:Hp阳性消化性溃疡患者血清CHI3L1水平升高,CHI3L1是消化性溃疡Hp感染的独立危险因素,与Hp感染类型、溃疡部位和疾病严重程度密切相关,在消化性溃疡Hp感染诊断中具有较高的临床价值。展开更多
目的:探究膀胱癌组织壳多糖酶3样蛋白1(chitosanase 3-like protein 1,CHI3L1)、Y性别决定基因7(sex determining region Y-box,SOX7)表达及与经尿道膀胱肿瘤电切术(transurethral resection of bladder tumors,TURBT)术后复发的关系。...目的:探究膀胱癌组织壳多糖酶3样蛋白1(chitosanase 3-like protein 1,CHI3L1)、Y性别决定基因7(sex determining region Y-box,SOX7)表达及与经尿道膀胱肿瘤电切术(transurethral resection of bladder tumors,TURBT)术后复发的关系。方法:收集2019年8月—2021年8月保定市第二医院收治的146例行TURBT的膀胱癌患者作为观察对象,取患者癌组织和癌旁组织,采用免疫组织化学法测定膀胱癌组织和癌旁组织CHI3L1、SOX7蛋白表达,对患者进行2年随访,根据术后复发情况,分为复发组32例和未复发组114例,采用logistic回归分析膀胱癌患者TURBT术后复发的影响因素,四格表分析膀胱癌组织CHI3L1、SOX7蛋白表达对TURBT术后复发的预测价值。结果:膀胱癌组织CHI3L1阳性表达率(65.75%)显著高于癌旁组织(34.93%),SOX7阳性表达率(41.10%)显著低于癌旁组织(73.29%)(P<0.05)。肿瘤数目多发、T1期的膀胱癌组织CHI3L1阳性表达和SOX7阴性表达的患者比例显著高于肿瘤数目单发、Ta期的患者比例(P<0.05)。CHI3L1是膀胱癌患者TURBT术后复发的独立危险因素,SOX7是复发的保护因素(P<0.05)。CHI3L1、SOX7联合预测术后复发的特异度、准确度高于各自单独预测,误诊率低于各自单独预测(P<0.05)。结论:在膀胱癌组织中CHI3L1表达水平较高,SOX7表达水平较低,二者与患者临床病理特征以及TURBT术后复发有关,可能作为膀胱癌患者行TURBT术后预后评估的标志物。展开更多
Background:Visinin-like protein-1(VILIP-1)and chitinase-3-like protein 1(CHI3L1 or YKL-40)in cerebrospinal fluid(CSF)are newly discovered markers indicating neuronal damage and microglial activation,respectively.Phosp...Background:Visinin-like protein-1(VILIP-1)and chitinase-3-like protein 1(CHI3L1 or YKL-40)in cerebrospinal fluid(CSF)are newly discovered markers indicating neuronal damage and microglial activation,respectively.Phosphorylated tau(p-tau)reflects the neuropathology of Alzheimer’s disease(AD)and is useful as diagnostic markers for AD.However,it is unknown whether these biomarkers have similar or complementary information in AD.Methods:We stratified 121 participants from the Alzheimer’s Disease Neuroimaging Initiative(ADNI)database into cognitively normal(CN),stable mild cognitive impairment(sMCI),progressive MCI(pMCI),and dementia due to AD.Analysis of covariance(ANOVA)and chi-square analyses,Spearman correlation,and logistic regression models were performed to test the demographic,associations between biomarkers,and diagnostic accuracies,respectively.Linear mixed-effects models were used to evaluate the effects of CSF amyloid-β(Aβ)on above biomarkers within diagnostic groups,the combination of diagnostic group and Aβstatus as predictor,and CSF biomarkers as predictors of AD features,including cognition measured by Mini–Mental State Examination(MMSE)and brain structure and white matter hyperintensity(WMH)measured by magnetic resonance imaging(MRI).Results:P-tau,VILIP-1,and YKL-40 were all predictors of AD diagnosis,but combinations of biomarkers did not improve the diagnostic accuracy(AUC 0.924 for p-tau,VILIP-1,and YKL-40)compared to p-tau(AUC 0.922).P-tau and VILIP-1 were highly correlated(r=0.639,p<0.001)and strongly associated with Aβpathology across clinical stages of AD,while YKL-40 was correlated with Aβpathology in CN and AD groups.VILIP-1 was associated with acceleration of cognitive decline,hippocampal atrophy,and expansion of ventricles in longitudinal analyses.YKL-40 was associated with hippocampal atrophy at baseline and follow-up,while p-tau was only associated with worsening WMH at baseline.Conclusions:CSF levels of p-tau,VILIP-1,and YKL-40 may have utility for discriminating between cognitively normal subjects and patients with AD.Increased levels of both VILIP-1 and YKL-40 may be associated with disease degeneration.These CSF biomarkers should be considered for future assessment in the characterization of the natural history of AD.展开更多
目的:分析柔肝化纤颗粒联合恩替卡韦治疗肝肾阴虚型慢性乙型肝炎纤维化患者的临床疗效及对血清壳多糖酶3样蛋白1、炎症因子水平的影响。方法:检索2016年1月至2019年1月在广西中医药大学第一附属医院住院的肝肾阴虚型慢性乙型肝炎纤维化...目的:分析柔肝化纤颗粒联合恩替卡韦治疗肝肾阴虚型慢性乙型肝炎纤维化患者的临床疗效及对血清壳多糖酶3样蛋白1、炎症因子水平的影响。方法:检索2016年1月至2019年1月在广西中医药大学第一附属医院住院的肝肾阴虚型慢性乙型肝炎纤维化患者180例,治疗组和对照组各90例,对照组采用恩替卡韦抗病毒治疗,治疗组在对照组基础上加用柔肝化纤颗粒,2组疗程均为48周,观察2组患者治疗前后血清壳多糖酶3样蛋白1、肝功能、肝纤4项、乙肝病毒DNA(hepatitis b virus-DNA,HBV-DNA)转阴率、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白介素-6(Tnterleukin-6,IL-6)、白介素-8(Interleukin-8,IL-8)及中医临床疗效等指标的变化。结果:治疗48周后,2组患者肝功能、肝纤4项、肝脏硬度值、HBV-DNA转阴率、中医临床疗效、血清壳多糖酶3样蛋白1及炎症因子水平均有不同程度改善,其中治疗组各项指标改善程度均优于对照组(P<0.05),差异有统计学意义。结论:在常规西医抗病毒治疗基础上加用柔肝化纤颗粒治疗肝肾阴虚型慢性乙型肝炎肝纤维化,可能通过降低患者血清壳多糖酶3样蛋白1和炎症因子水平起到减轻患者炎症反应、抗肝纤维化的作用。展开更多
文摘目的探讨血清壳多糖酶3样蛋白1(chitinase-3-like protein 1,CHI3L1)、甲胎蛋白(alpha fetoprotein,AFP)和γ-谷氨酰转移酶(γ-glutamyl transferase,GGT)检测在乙型肝炎病毒(hepatitis B virus,HBV)感染相关肝癌诊断中的临床应用价值。方法选取2021年7月—2023年7月在玉林市第一人民医院就诊HBV病毒感染相关的50例肝癌患者,50例肝硬化患者,50例慢性乙型肝炎患者以及50名同期健康体检者作为研究对象。比较4组研究对象血清中CHI3L1、AFP、GGT、丙氨酸氨基转移酶(alanine aminotransferase,ALT)、天门冬氨酸氨基转移酶(aspartate aminotransferase,AST)等水平的差异,用受试者工作特征(receiver operating characteristic curve,ROC)曲线评估各指标在肝癌中的诊断价值。结果肝炎组、肝硬化组、肝癌组的CHI3L1、AST、ALT水平均高于对照组,肝癌组AFP、GGT水平高于对照组,差异有统计学意义(P<0.05)。与肝炎组比较,肝硬化组及肝癌组的CHI3L1、AFP、GGT、AST、ALT水平均升高,差异有统计学意义(P<0.05)。与肝硬化组比较,肝癌组的CHI3L1、AFP、GGT、AST水平均升高,差异有统计学意义(P<0.05)。ROC曲线分析显示,CHI3L1、AFP、GGT联合时的曲线下面积(area under the curve,AUC)最大(AUC=0.936)。Spearman相关分析结果显示,CHI3L1与AST呈正相关(r=0.414,P=0.003),AFP与GGT呈正相关(r=0.437,P=0.002),AFP与AST呈正相关(r=0.504,P<0.001),GGT与AST呈正相关(r=0.759,P<0.001),GGT与ALT呈正相关(r=0.636,P<0.001)。结论CHI3L1、AFP及GGT联合检测可提高肝癌的诊断价值,对临床肝癌患者诊疗有重要作用。
基金the Research Ethics Committee of The First Affiliated Hospital of Zhejiang University School of Medicine(No.2018-918).
文摘Background:Serum chitinase-3-like protein 1(CHI3L1)is a potential biomarker for fibrosis assessment.We aimed to evaluate serum CHI3L1 as a noninvasive diagnostic marker for chronic hepatitis B virusrelated fibrosis.Methods:Serum CHI3L1 levels were measured by ELISA in 134 chronic hepatitis B(CHB)patients.Significant fibrosis was defined as a liver stiffness>9.7 kPa.The performance of CHI3L1 was assessed and compared to that of other noninvasive tests by receiver operating characteristic(ROC)analysis.Results:Serum CHI3L1 levels were significantly higher in CHB patients with significant hepatic fibrosis(≥F2)than in those without significant hepatic fibrosis(<F2)(56.5 ng/mL vs.81.9 ng/mL,P<0.001).In CHB patients,the specificity and sensitivity of CHI3L1 for predicting significant fibrosis were 75.6%and 59.1%,respectively,with a cut-off of 76.0 ng/mL and an area under the ROC curve of 0.728(95%CI:0.637–0.820).Conclusions:Serum CHI3L1 levels could be an effective new serological biomarker for the diagnosis of liver fibrosis.Moreover,CHI3L1 is feasible in monitoring disease progression.
文摘目的:基于以壳多糖酶3样蛋白1(chitinase-3-like protein 1,CHI3L1)为主要评价指标,观察化肝纤方联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床疗效。方法:将80例确诊为慢性乙型肝炎肝纤维化的患者采用随机数字表法的方式分为对照组和治疗组各40例,2组均采用一般西医综合治疗,治疗组在此基础上仅加用化肝纤方,疗程为8周,比较2组治疗前后的血清CHI3L1水平、肝功能(转氨酶、总胆红素)、肝纤4项、Fibrosis 4 Score(FIB-4指数)、肝脏硬度值(liver stiffness measurement,LSM)、乙肝病毒DNA(hepatitis B virus-DNA,HBV-DNA)转阴率、中医症状评分等观察指标。结果:治疗后治疗组血清CHI3L1水平、肝功能(转氨酶、总胆红素)、肝纤4项、FIB-4指数、肝脏硬度值、HBV-DNA转阴率、中医症状评分均低于对照组,差异有统计学意义。结论:化肝纤方联合恩替卡韦治疗慢性乙型肝炎相关肝纤维化有较好的临床疗效,可改善慢性乙型肝炎肝纤维化患者肝脏生理水平及肝纤维化程度,降低血清CHI3L1、肝纤4项、FBI-4指数、肝脏硬度值,提高乙肝病毒DNA转阴率,改善肝功能及临床症状,延缓疾病的进展,提高患者生存质量。
基金Supported by the National Natural Science Foundation of China(No.81900829,No.82070963)the Xiamen Medical and Health Guiding Project Fund Project(No.3502Z20214ZD1214)+1 种基金the Guangdong Basic and Applied Basic Research Foundation(No.2019A1515011234)the Science and Technology Innovation Committee of Shenzhen(No.JCYJ20210324125614039)。
文摘AIM:To evaluate the potential of two trabecular meshwork(TM)-specific promoters,Chitinase 3-like 1(Ch3L1)and matrix gla protein(MGP),for improving specificity and safety in glaucoma gene therapy based on self-complementary AAV2(scAAV2)vector technologies.METHODS:An scAAV2 vector with C3 transferase(C3)as the reporter gene(scAAV2-C3)was selected.The scAAV2-C3 vectors were driven by Ch3L1(scAAV2-Ch3L1-C3),MGP(scAAV2-MGP-C3),enhanced MGP(scAAV2-eMGP-C3)and cytomegalovirus(scAAV2-CMV-C3),respectively.The cultured primary human TM cells were treated with each vector at different multiplicities of infections.Changes in cell morphology were observed by phase contrast microscopy.Actin stress fibers and Rho GTPases/Rho-associated protein kinase pathway-related molecules were assessed by immunofluorescence staining,real-time quantitative polymerase chain reaction and Western blot.Each vector was injected intracamerally into the one eye of each rat at low and high doses respectively.In vivo green fluorescence was visualized by a Micron III Retinal Imaging Microscope.Intraocular pressure(IOP)was monitored using a rebound tonometer.Ocular responses were evaluated by slit-lamp microscopy.Ocular histopathology analysis was examined by hematoxylin and eosin staining.RESULTS:In TM cell culture studies,the vectormediated C3 expression induced morphologic changes,disruption of actin cytoskeleton and reduction of fibronectin expression in TM cells by inhibiting the Rho GTPases/Rhoassociated protein kinase signaling pathway.At the same dose,these changes were significant in TM cells treated with scAAV2-CMV-C3 or scAAV2-Ch3L1-C3,but not in cells treated with scAAV2-eMGP-C3 or scAAV2-MGP-C3.At lowinjected dose,the IOP was significantly decreased in the scAAV2-Ch3L1-C3-injected eyes but not in scAAV2-MGPC3-injected and scAAV2-eMGP-C3-injected eyes.At highinjected dose,significant IOP reduction was observed in the scAAV2-eMGP-C3-injected eyes but not in scAAV2-MGP-C3-injected eyes.Similar to scAAV2-CMV-C3,scAAV2-Ch3L1-C3 vector showed efficient transduction both in the TM and corneal endothelium.In anterior segment tissues of scAAV2-eMGP-C3-injected eyes,no obvious morphological changes were found except for the TM.Inflammation was absent.CONCLUSION:In scAAV2-transduced TM cells,the promoter-driven efficiency of Ch3L1 is close to that of cytomegalovirus,but obviously higher than that of MGP.In the anterior chamber of rat eye,the transgene expression pattern of scAAV2 vector is presumably affected by MGP promoter,but not by Ch3L1 promoter.These findings would provide a useful reference for improvement of specificity and safety in glaucoma gene therapy using scAAV2 vector.
文摘目的:探究膀胱癌组织壳多糖酶3样蛋白1(chitosanase 3-like protein 1,CHI3L1)、Y性别决定基因7(sex determining region Y-box,SOX7)表达及与经尿道膀胱肿瘤电切术(transurethral resection of bladder tumors,TURBT)术后复发的关系。方法:收集2019年8月—2021年8月保定市第二医院收治的146例行TURBT的膀胱癌患者作为观察对象,取患者癌组织和癌旁组织,采用免疫组织化学法测定膀胱癌组织和癌旁组织CHI3L1、SOX7蛋白表达,对患者进行2年随访,根据术后复发情况,分为复发组32例和未复发组114例,采用logistic回归分析膀胱癌患者TURBT术后复发的影响因素,四格表分析膀胱癌组织CHI3L1、SOX7蛋白表达对TURBT术后复发的预测价值。结果:膀胱癌组织CHI3L1阳性表达率(65.75%)显著高于癌旁组织(34.93%),SOX7阳性表达率(41.10%)显著低于癌旁组织(73.29%)(P<0.05)。肿瘤数目多发、T1期的膀胱癌组织CHI3L1阳性表达和SOX7阴性表达的患者比例显著高于肿瘤数目单发、Ta期的患者比例(P<0.05)。CHI3L1是膀胱癌患者TURBT术后复发的独立危险因素,SOX7是复发的保护因素(P<0.05)。CHI3L1、SOX7联合预测术后复发的特异度、准确度高于各自单独预测,误诊率低于各自单独预测(P<0.05)。结论:在膀胱癌组织中CHI3L1表达水平较高,SOX7表达水平较低,二者与患者临床病理特征以及TURBT术后复发有关,可能作为膀胱癌患者行TURBT术后预后评估的标志物。
基金Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative(ADNI)(National Institutes of Health Grant U01 AG024904)DOD ADNI(Department of Defense award number W81XWH-12-2-0012)+4 种基金This work was supported by the Weston Brain Institute,Canadian Institutes of Health Research(CIHR)(MOP-11-51-31,PR-N)the Alzheimer’s Association(NIRG-12-92090,NIRP-12-259245,PR-N)Fonds de Recherche du Québec-Santé(FRQSChercheur Boursier,PR-N)Clinical key specialist fund,the Department of Neurology,the First Affiliated Hospital of Chongqing Medical University(scholarship,HZ).
文摘Background:Visinin-like protein-1(VILIP-1)and chitinase-3-like protein 1(CHI3L1 or YKL-40)in cerebrospinal fluid(CSF)are newly discovered markers indicating neuronal damage and microglial activation,respectively.Phosphorylated tau(p-tau)reflects the neuropathology of Alzheimer’s disease(AD)and is useful as diagnostic markers for AD.However,it is unknown whether these biomarkers have similar or complementary information in AD.Methods:We stratified 121 participants from the Alzheimer’s Disease Neuroimaging Initiative(ADNI)database into cognitively normal(CN),stable mild cognitive impairment(sMCI),progressive MCI(pMCI),and dementia due to AD.Analysis of covariance(ANOVA)and chi-square analyses,Spearman correlation,and logistic regression models were performed to test the demographic,associations between biomarkers,and diagnostic accuracies,respectively.Linear mixed-effects models were used to evaluate the effects of CSF amyloid-β(Aβ)on above biomarkers within diagnostic groups,the combination of diagnostic group and Aβstatus as predictor,and CSF biomarkers as predictors of AD features,including cognition measured by Mini–Mental State Examination(MMSE)and brain structure and white matter hyperintensity(WMH)measured by magnetic resonance imaging(MRI).Results:P-tau,VILIP-1,and YKL-40 were all predictors of AD diagnosis,but combinations of biomarkers did not improve the diagnostic accuracy(AUC 0.924 for p-tau,VILIP-1,and YKL-40)compared to p-tau(AUC 0.922).P-tau and VILIP-1 were highly correlated(r=0.639,p<0.001)and strongly associated with Aβpathology across clinical stages of AD,while YKL-40 was correlated with Aβpathology in CN and AD groups.VILIP-1 was associated with acceleration of cognitive decline,hippocampal atrophy,and expansion of ventricles in longitudinal analyses.YKL-40 was associated with hippocampal atrophy at baseline and follow-up,while p-tau was only associated with worsening WMH at baseline.Conclusions:CSF levels of p-tau,VILIP-1,and YKL-40 may have utility for discriminating between cognitively normal subjects and patients with AD.Increased levels of both VILIP-1 and YKL-40 may be associated with disease degeneration.These CSF biomarkers should be considered for future assessment in the characterization of the natural history of AD.
文摘目的:分析柔肝化纤颗粒联合恩替卡韦治疗肝肾阴虚型慢性乙型肝炎纤维化患者的临床疗效及对血清壳多糖酶3样蛋白1、炎症因子水平的影响。方法:检索2016年1月至2019年1月在广西中医药大学第一附属医院住院的肝肾阴虚型慢性乙型肝炎纤维化患者180例,治疗组和对照组各90例,对照组采用恩替卡韦抗病毒治疗,治疗组在对照组基础上加用柔肝化纤颗粒,2组疗程均为48周,观察2组患者治疗前后血清壳多糖酶3样蛋白1、肝功能、肝纤4项、乙肝病毒DNA(hepatitis b virus-DNA,HBV-DNA)转阴率、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白介素-6(Tnterleukin-6,IL-6)、白介素-8(Interleukin-8,IL-8)及中医临床疗效等指标的变化。结果:治疗48周后,2组患者肝功能、肝纤4项、肝脏硬度值、HBV-DNA转阴率、中医临床疗效、血清壳多糖酶3样蛋白1及炎症因子水平均有不同程度改善,其中治疗组各项指标改善程度均优于对照组(P<0.05),差异有统计学意义。结论:在常规西医抗病毒治疗基础上加用柔肝化纤颗粒治疗肝肾阴虚型慢性乙型肝炎肝纤维化,可能通过降低患者血清壳多糖酶3样蛋白1和炎症因子水平起到减轻患者炎症反应、抗肝纤维化的作用。
